We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Inhibition of Cholesterol Esterification Suppresses Growth of Pancreatic Cancer Cells

By LabMedica International staff writers
Posted on 18 May 2016
A team of cancer researchers has suggested that controlling cholesterol metabolism within tumor cells represents a novel approach towards treating the disease.

Investigators at Purdue University (West Lafayette, IN, USA) used stimulated Raman scattering (SRS) microscopy and Raman spectroscopy to examine pancreatic cancer cells. More...
Raman spectroscopy exploits the inelastic scattering (so-called “Raman” scattering) phenomena to detect spectral signatures of important disease progression biomarkers, including lipids, proteins, and amino acids.

In a paper in the May 2, 2016, online edition of the journal Oncogene the investigators reported finding an aberrant accumulation of cholesteryl esters in human pancreatic cancer specimens and cell lines, mediated by the acyl-CoA cholesterol acyltransferase-1 (ACAT-1) enzyme.

ACAT catalyzes the intracellular esterification of cholesterol and formation of cholesteryl esters. The esterification of cholesterol mediated by ACAT is functionally significant for several reasons. ACAT-mediated esterification of cholesterol limits its solubility in the cell membrane lipids and thus promotes accumulation of cholesterol ester in the fat droplets within cytoplasm; this process is important because the toxic accumulation of free cholesterol in various cell membrane fractions is prevented.

The investigators found that expression of ACAT-1 showed a correlation with poor patient survival. Blocking cholesterol esterification, either by an ACAT-1 inhibitor, such as the drug avasimibe, or by shRNA knockdown, significantly suppressed tumor growth and metastasis in a mouse model of pancreatic cancer. At the molecular level, it was found that ACAT-1 inhibition increased intracellular free cholesterol level, which was associated with elevated endoplasmic reticulum stress and caused apoptosis.

"We show for the first time that if you control the cholesterol metabolism you could reduce pancreatic cancer spread to other organs," said senior author Dr. Ji-Xin Cheng, professor of chemistry and biomedical engineering at Purdue University. "We chose pancreatic cancer to test this approach because it is the most aggressive disease of all the cancers. By using avasimibe, a potent inhibitor of ACAT-1, we found that pancreatic cancer cells were much more sensitive to ACAT-1 inhibition than normal cells. The drug did not induce weight loss, and there was no apparent organ toxicity in the liver, kidney, lung, and spleen."

Related Links:
Purdue University


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Clinical Informatics Platform
CLARION™
New
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.